Anil Shanker

2.3k total citations
69 papers, 1.7k citations indexed

About

Anil Shanker is a scholar working on Immunology, Oncology and Molecular Biology. According to data from OpenAlex, Anil Shanker has authored 69 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Immunology, 30 papers in Oncology and 26 papers in Molecular Biology. Recurrent topics in Anil Shanker's work include Immune Cell Function and Interaction (23 papers), Immunotherapy and Immune Responses (18 papers) and CAR-T cell therapy research (12 papers). Anil Shanker is often cited by papers focused on Immune Cell Function and Interaction (23 papers), Immunotherapy and Immune Responses (18 papers) and CAR-T cell therapy research (12 papers). Anil Shanker collaborates with scholars based in United States, France and India. Anil Shanker's co-authors include Roman V. Uzhachenko, Thomas J. Sayers, Anshu Malhotra, Maria Teresa P. de Aquino, Sukh Mahendra Singh, Akiko Shimamoto, Hideo Yagita∥, Samuel T. Pellom, Ajit Sodhi and David P. Carbone and has published in prestigious journals such as Nature, SHILAP Revista de lepidopterología and The Journal of Immunology.

In The Last Decade

Anil Shanker

66 papers receiving 1.7k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Anil Shanker United States 25 895 693 601 167 131 69 1.7k
Mingye Feng United States 20 1.3k 1.4× 797 1.2× 601 1.0× 129 0.8× 74 0.6× 36 2.3k
Evelyn P. Murphy Ireland 29 864 1.0× 712 1.0× 322 0.5× 182 1.1× 108 0.8× 46 2.1k
В. М. Писарев Russia 20 1.4k 1.6× 674 1.0× 715 1.2× 161 1.0× 72 0.5× 73 2.3k
Concepció Soler Spain 29 685 0.8× 1.5k 2.1× 417 0.7× 185 1.1× 55 0.4× 68 2.8k
Shinji Oki Japan 21 1.2k 1.3× 601 0.9× 235 0.4× 133 0.8× 72 0.5× 50 2.0k
Sabine Adam‐Klages Germany 28 674 0.8× 1.4k 2.0× 343 0.6× 246 1.5× 41 0.3× 51 2.1k
Erika Ortolan Italy 18 470 0.5× 483 0.7× 353 0.6× 57 0.3× 166 1.3× 31 1.6k
Anna Longo Italy 21 757 0.8× 384 0.6× 214 0.4× 65 0.4× 120 0.9× 57 1.5k
Rajkumar Noubade United States 20 1.1k 1.3× 585 0.8× 338 0.6× 97 0.6× 77 0.6× 30 2.0k
Tracey L. Papenfuss United States 20 921 1.0× 546 0.8× 330 0.5× 248 1.5× 29 0.2× 40 1.7k

Countries citing papers authored by Anil Shanker

Since Specialization
Citations

This map shows the geographic impact of Anil Shanker's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anil Shanker with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anil Shanker more than expected).

Fields of papers citing papers by Anil Shanker

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anil Shanker. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anil Shanker. The network helps show where Anil Shanker may publish in the future.

Co-authorship network of co-authors of Anil Shanker

This figure shows the co-authorship network connecting the top 25 collaborators of Anil Shanker. A scholar is included among the top collaborators of Anil Shanker based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anil Shanker. Anil Shanker is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Sakwe, Amos M., Alexander T. Hawkins, M. Kay Washington, et al.. (2025). Functional characterization of novel anti-DEFA5 monoclonal antibody clones 1A8 and 4F5 in inflammatory bowel disease colitis tissues. Inflammation Research. 74(1). 30–30.
2.
Shanker, Anil. (2025). How my institution strengthened research despite chronic underfunding. Nature. 648(8094). 500–500.
3.
Uzhachenko, Roman V., Thanigaivelan Kanagasabai, Menaka C. Thounaojam, et al.. (2025). CD8+ T–NK cell crosstalk establishes preemptive immunosurveillance to eliminate antigen–escape tumors. Frontiers in Immunology. 16. 1593913–1593913. 1 indexed citations
4.
Kanagasabai, Thanigaivelan, et al.. (2024). Bortezomib in Combination with Physachenolide C Reduces the Tumorigenic Properties of KRASmut/P53mut Lung Cancer Cells by Inhibiting c-FLIP. Cancers. 16(3). 670–670. 1 indexed citations
5.
Uzhachenko, Roman V., Akiko Shimamoto, Sanika Chirwa, et al.. (2022). Mitochondrial Fus1/Tusc2 and cellular Ca2+ homeostasis: tumor suppressor, anti-inflammatory and anti-aging implications. Cancer Gene Therapy. 29(10). 1307–1320. 10 indexed citations
6.
Tewary, Poonam, Alan D. Brooks, Ya-Ming Xu, et al.. (2021). Small-Molecule Natural Product Physachenolide C Potentiates Immunotherapy Efficacy by Targeting BET Proteins. Cancer Research. 81(12). 3374–3386. 12 indexed citations
7.
8.
Shanker, Anil, et al.. (2019). Notch as an Immunologic Basis of Cancer Disparities.. PubMed Central. 3. e1–e10. 1 indexed citations
9.
Uzhachenko, Roman V. & Anil Shanker. (2019). CD8+ T Lymphocyte and NK Cell Network: Circuitry in the Cytotoxic Domain of Immunity. Frontiers in Immunology. 10. 1906–1906. 85 indexed citations
10.
Patel, Jyoti D., Henry Wagner, D. Carbone, et al.. (2018). MA05.01 E6508: Phase II Study of Immunotherapy with Tecemotide and Bevacizumab after Chemoradiation in Unresectable Stage III NS-NSCLC. Journal of Thoracic Oncology. 13(10). S370–S370. 1 indexed citations
11.
Uzhachenko, Roman V., Kyungho Park, Anwari Akhter, et al.. (2015). Multivalent Forms of the Notch Ligand DLL-1 Enhance Antitumor T-cell Immunity in Lung Cancer and Improve Efficacy of EGFR-Targeted Therapy. Cancer Research. 75(22). 4728–4741. 46 indexed citations
12.
Shanker, Anil, Samuel T. Pellom, Menaka C. Thounaojam, et al.. (2015). Bortezomib Improves Adoptive T-cell Therapy by Sensitizing Cancer Cells to FasL Cytotoxicity. Cancer Research. 75(24). 5260–5272. 23 indexed citations
13.
Shanker, Anil, Mikhail M. Dikov, & David P. Carbone. (2015). Promise of Immunotherapy in Lung Cancer. Progress in tumor research. 42. 95–109. 2 indexed citations
14.
Ascierto, Maria Libera, Michael O. Idowu, Yingdong Zhao, et al.. (2013). Molecular signatures mostly associated with NK cells are predictive of relapse free survival in breast cancer patients. Journal of Translational Medicine. 11(1). 145–145. 81 indexed citations
15.
Huang, Yuhui, Luping Lin, Anil Shanker, et al.. (2011). Resuscitating Cancer Immunosurveillance: Selective Stimulation of DLL1-Notch Signaling in T cells Rescues T-cell Function and Inhibits Tumor Growth. Cancer Research. 71(19). 6122–6131. 62 indexed citations
16.
Brooks, Alan D., Kristen M. Jacobsen, Wenqing Li, Anil Shanker, & Thomas J. Sayers. (2010). Bortezomib Sensitizes Human Renal Cell Carcinomas to TRAIL Apoptosis through Increased Activation of Caspase-8 in the Death-Inducing Signaling Complex. Molecular Cancer Research. 8(5). 729–738. 54 indexed citations
17.
Shanker, Anil, Alan D. Brooks, Kristen M. Jacobsen, et al.. (2009). Antigen Presented by Tumors In vivo Determines the Nature of CD8+ T-Cell Cytotoxicity. Cancer Research. 69(16). 6615–6623. 38 indexed citations
18.
Shanker, Anil, Ari D. Brooks, John W. Wine, et al.. (2008). Treating Metastatic Solid Tumors With Bortezomib and a Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Receptor Agonist Antibody. JNCI Journal of the National Cancer Institute. 100(9). 649–662. 69 indexed citations
19.
Shanker, Anil, Grégory Verdeil, Michel Buferne, et al.. (2007). CD8 T Cell Help for Innate Antitumor Immunity. The Journal of Immunology. 179(10). 6651–6662. 69 indexed citations
20.
Roy, Rajat, Sukh Mahendra Singh, & Anil Shanker. (2000). Mechanism of thymocyte apoptosis induced by serum of tumor-bearing host: the molecular events involved and their inhibition by thymosin α-1. International Journal of Immunopharmacology. 22(4). 309–321. 22 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Mingye Feng Breakdown of academic impact, for papers by Evelyn P. Murphy Breakdown of academic impact, for papers by В. М. Писарев Breakdown of academic impact, for papers by Concepció Soler Breakdown of academic impact, for papers by Shinji Oki Breakdown of academic impact, for papers by Sabine Adam‐Klages Breakdown of academic impact, for papers by Erika Ortolan Breakdown of academic impact, for papers by Anna Longo Breakdown of academic impact, for papers by Rajkumar Noubade Breakdown of academic impact, for papers by Tracey L. Papenfuss
Rankless by CCL
2026